The goal of this application is to establish a Clinical Center of TrialNet at the University of California at San Francisco (UCSF) Diabetes Center, with the ultimate long-term objective to develop therapies to prevent the onset of Type 1 diabetes mellitus (T1DM). UCSF is uniquely positioned to serve as a study site for this multicenter trial, given a strong established diabetes program, a large population base for subject recruitment, and an established track record with clinical research and autoimmune interventions for T1DM. Clinicians at the UCSF Diabetes Center now provide care for approximately 3400 patients, with 100 new patients with Type 1 diabetes each year. In addition, the center has investigators with extensive experience in both clinical and basic science research, and with NIH-funded Pediatric and General Clinical Research Centers. The investigators are well positioned to recruit subjects from within the UCSF system, and widely from a preexisting referral net throughout Northern California. The diversity of the population suggests that subjects will be recruited from a variety of ethnicities. This application will build on UCSF?s past role as an Affiliate in the Diabetes Prevention Trial-1 (DPT-1). Specifically, the study goals are:
Specific Aim 1 : To implement and continue the DPT-1 protocols. This includes creation of an infrastructure that will enhance follow-up of subjects already entered into the DPT-1, as well as recruitment to screen and stage new subjects, with subsequent enrollment of those at intermediate risk into the oral insulin study arm.
Specific Aim 2 : To participate in other trials developed through TrialNet.
Specific Aim 3 : To implement a novel protocol involving treatment of individuals at high risk for Type 1 diabetes with a non-FcR binding anti-CD3 monoclonal antibody (mAb) (hOKT3g1(Ala-Ala)). An ongoing Phase I/II trial of this agent in new onset T1DM has shown that administration of the drug is safe, and has suggested efficacy in preserving insulin secretory capacity over time. Our rationale for this application is that if similar effects are seen in patients in whom the earliest signs of beta cell dysfunction are detected, and then progression to diabetes might be prevented.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK061010-03
Application #
6660343
Study Section
Special Emphasis Panel (ZDK1-GRB-C (O1))
Program Officer
Leschek, Ellen W
Project Start
2001-09-29
Project End
2008-06-30
Budget Start
2003-09-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$266,390
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225
Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317
Sosenko, Jay M; Geyer, Susan; Skyler, Jay S et al. (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes 19:403-409
Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92
Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:
Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:
Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486
Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276
Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474

Showing the most recent 10 out of 83 publications